Rhythm disorders in comorbid patients. Efficiency and safety of antiarrhythmic therapy
The urgency of the problem of treating cardiovascular diseases of ischemic origin and preventing the development of fatal complications is today one of the most important areas of modern medicine. So, over the past few decades, cardiovascular pathology has firmly occupied the first place in the structure of mortality from all causes. Atrial fibrillation (AF) is the most common arrhythmia in clinical practice, accounting for approximately a third of hospitalizations for cardiac arrhythmias. The prevalence of atrial fibrillation in the general population increases with age and with a combination of its associated clinical conditions such as coronary heart disease, hypertension, heart failure, obesity, diabetes mellitus, thyrotoxicosis. The most difficult is to predict the effect and choice of drug therapy, depending on the presence and combination of two or more pathological conditions. In 2017, the Russian recommendations "Comorbid pathology in clinical practice. Diagnostic and treatment algorithms", which discusses modern approaches to the choice of antiarrhythmic therapy in patients with atrial fibrillation, depending on the associated pathology.